✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
SA OXYPHARM
SA à directoire · Active since 1984
Overview
SA OXYPHARM is a SA à directoire registered in rouen, France, since 1984. With reported revenue of 151.2M EUR in 2024. Its TraceComp score of 85 (A) indicates solid fundamentals and low apparent risk. With 42 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 329879050
- Legal Form
- SA à directoire
- Registered
- 1984-03-20
- Address
- rouen
Financial Profile
Latest filed accounts: FY 2024
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
12 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| GUILLAUME MICHEL ALEXANDRE | Directeur Général | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Public Contracts Won
Awarded 16 public-sector contracts totalling EUR 54,948,500 (DECP).
Which public buyers, contract titles, values and award dates.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Corporate Group & Ownership
Parent entities from the GLEIF global ownership graph (LEI Level 2).
| Relationship | Parent entity | Country |
|---|---|---|
| Direct parent | SOCIETE PHARMACEUTIQUE EUROPEENNE DE SERVICES ET D'EQUIPEMENTS | FR |
Risk Signals
No adverse legal events have been recorded for this company.
- Profitable: positive net income in FY 2024
Similar Companies
Data Sources & Freshness
Data sourced from: official public registries.